

Gastroenterology

Volume 169 / Issue 5

October 2025

www.gastrojournal.org

Contents

ON THE COVER

Gastroenterology



Global Consensus Recommendations for MASLD and MASH: A Delphi Process. See article by Younossi, et al, page 1017 for additional information.

COMMENTARIES

- 761 Heavy Metals and Inflammatory Bowel Disease**
S. Narvey, J.-E. Ghia, R. A. Marrie, H. Armstrong, and C. N. Bernstein
- 767 PNPLA3 Inhibition and Cardiometabolic Risk: Reassessing Dyslipidemia and Atherosclerotic Cardiovascular Disease Concerns**
S. Guo, E. Garcia-Medel, T. Schluep, R. Loomba, and N. J. Leeper

DIVERSITY, EQUITY, AND INCLUSION IN GI

- 771 Evaluating Disparities in Recurrent *Clostridioides difficile* Infection and Fecal Microbiota Transplant Treatment Using Geospatial and Social Vulnerability Analytic Tools**
N. Mehta, K. Little, M. H. Woodworth, D. Goodenough, R. Dhonau, and S. K. Fridkin

MENTORING, EDUCATION, AND TRAINING CORNER

- 776 Deconstructing Diagnostic Upper Endoscopy for the Novice Learner: A Delphi Survey of Gastroenterology Program Directors**
N. L. Kumar, R. F. Flanagan, A. E. Mikolajczyk, and J. L. Sewell

GASTRO CURBSIDE CONSULT

- 781 A Rare Cause of Rapid Progression to Intestinal Failure**
E. S. L. Low, J. Lokan, and D. Wong
- 785 A Rare Cause of Refractory Melena and Recurrent Intestinal Obstruction**
P. Yan, X. Xu, and J. Li
- 790 A Rare Case of Ileocolitis**
P. Perremans, G. De Hertogh, and B. Verstockt

V Video

CGH Related article in CGH

Hot Papers From New Investigators

CME CME quiz

E Editorial accompanies this article

www Additional online content available

COV Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc., 1600 John F. Kennedy Boulevard, Suite 1600, Philadelphia, PA 1910, United States. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 450 Fame Avenue, Hanover, PA 17331, USA. 2025 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

- 793 **A Rare Treatable Cause of Dysphagia and Odynophagia in a Lung Transplant Recipient**
A. Ahmed, L. Khanna, and A. Sharma

REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

- 797 **Regulation of Hepatic Stellate Cell Phenotypes in Metabolic Dysfunction-Associated Steatohepatitis**
T. Kisseleva, S. Ganguly, R. Murad, A. Wang, and D. A. Brenner

- 813 **Pharmacomicrobiomics: The Role of the Gut Microbiome in Immunomodulation and Cancer Therapy**
L. A. Bolte, J. R. Björk, R. Gacesa, and R. K. Weersma

GUIDELINES

- 828 **AGA Clinical Practice Guideline on Management of Gastroparesis**
K. Staller, H. P. Parkman, K. B. Greer, D. A. Leiman, M. J. Zhou, S. Singh, M. Camilleri, and O. Altayar, on behalf of the AGA Clinical Guidelines Committee

- 862 **Spotlight: Management of Gastroparesis**
H. P. Parkman, K. Staller, K. B. Greer, D. A. Leiman, M. J. Zhou, S. Singh, M. Camilleri, and O. Altayar

- 863 **Canadian Association of Gastroenterology Clinical Practice Guideline for the Endoscopic Management of Nonvariceal Nonpeptic Ulcer Upper Gastrointestinal Bleeding**
A. N. Barkun, L. Laine, G. I. Leontiadis, I. M. Gralnek, N. Carman, M. Ibrahim, M. Sey, A. A. Alali, M. W. Carroll, L. Hookey, M. Borgiaonkar, D. Armstrong, J. Y. W. Lau, N. Forbes, R. Pittayanon, and F. Tse

ORIGINAL RESEARCH

Full Reports

Inflammatory Bowel Disease

- 892 **Tumor Necrosis Factor-Like Ligand 1A/Death Receptor 3 Signaling Regulates the Generation of Pathogenic T Helper 9 Cells in Experimental Crohn's Disease**
P. Menghini, L. F. Buttó, A. Gomez-Nguyen, N. Aladyshkina, K.-A. Buela, A. Osme, R. Chan, H. L. Wargo, S. De Santis, G. Bamias, T. T. Pizarro, and F. Cominelli

The death receptor 3/tumor necrosis factor-like ligand 1A signaling pathway encourages the development of T helper 9 cells, making them more likely to cause harmful inflammation in the gut.

- 909 **Structural Variations in Ulcerative Colitis-associated *Escherichia coli* Reduce Fructose Utilization and Aggravate Inflammation Under High-Fructose Diet**
X. Wu, Y. Li, P. Li, G. Lu, J. Wu, Z. Wang, Q. Wen, B. Cui, J. Wang, and F. Zhang

The deletions of fructose utilization *scrK* gene in *Escherichia coli* from patients with ulcerative colitis led to fructose-dependent aggravation of colitis.

- 925 **Fidaxomicin Reduces Collagen Expression in Intestinal Fibroblasts Via Platelet-Derived Growth Factor Receptor Beta and Glycogen Synthase Kinase-3 Beta Inhibition**
S. Irwin, M. van Daelen, I. Almaraz, R. Park, B. Nelson, S. Mahurkar-Joshi, F. Rieder, D. Q. Shih, W. Ho, B. Limketkai, and H. W. Koon

The authors discovered new molecular targets in intestinal fibrosis. Fidaxomicin inhibits these molecular targets, reduces collagen expression in intestinal fibroblasts, and ameliorates intestinal fibrosis.

Functional GI Disease

942 **Inadequate Propulsion and Pelvic Floor Relaxation in Dyssynergic Defecation: Insights From Synchronous Proctomanometry**

R. Lamichhane, M. Gautam, J. G. Fletcher, K. R. Bailey, J. Chen, K. J. Feuerhak, and A. E. Bharucha

The mechanisms of normal defecation, which require coordinated rectal propulsion and pelvic floor relaxation, differ between men and women. Most constipated patients with dyssynergic (ie, dyscoordinated) defecation have both an impaired rectal propulsive force and impaired relaxation.

958 **Efficacy of ACupuncTure in Irritable bOwel syNdrome (ACTION): A Multicenter Randomized Controlled Trial**

J.-W. Yang, L.-Y. Qi, S.-Y. Yan, Y.-F. She, Y. Li, L.-L. Chi, H. Hu, L.-Q. Wang, C.-C. Ji, B.-Q. Wu, Z.-T. Fu, S.-J. Li, N.-N. Yang, Y. Wang, and C.-Z. Liu

Acupuncture is widely used in clinics but without sufficient evidence to treat irritable bowel syndrome. This trial found that 15 sessions of acupuncture treatment over 6 weeks produced significant and sustained improvement in abdominal pain and stool consistency.

Gut Microbiota

970 **Dietary Fiber Modulates the Window of Susceptibility to *Clostridioides difficile* Infection**

K. K. Hewlett, A. PeBenito, A. L. Hecht, C. Tiffany, C. Tanes, R. C. Glover, J. A. Fawad, E. S. Friedman, J. C. Reynolds, K. Bittinger, J. D. Lewis, G. D. Wu, N. K. Ahuja, and J. P. Zackular

Eating a low-fiber diet after taking antibiotics is linked to disruption of the structure and function of the gut microbiota, which corresponds to prolonged susceptibility to *Clostridioides difficile* infection.

Pancreas

983 **KRASG12D Cells Override Homeostatic Cell Elimination Mechanisms in Adult Pancreas Via Wnt5a and Cell Dormancy**

B. Salvador-Barbero, M. Alatsatianos, J. P. Morton, O. J. Sansom, and C. Hogan

In the pancreas, cells with cancer-causing mutations are typically "kicked out" of the tissue, preventing cancer. Some mutant cells survive by activating specific signals to avoid being expelled.

Hepatobiliary

1000 **Adeno-associated Virus-mediated Silencing of Sox4 Leads to Long-Term Amelioration of Liver Phenotypes in Mouse Models of Alagille Syndrome**

D. Fox, J. Xie, J. L. Burwinkel, J. M. Adams, K. Chetal, M. Keivandarian, Y. Faingelernt, S. Subramanian, M. F. Lopez, A. L. Peters, N. Salomonis, N. Zarrin-Khameh, G. Gao, S. S. Huppert, and H. Jafar-Nejad

Preclinical studies demonstrate that reducing SOX4 levels by gene therapy leads to significant and lasting improvement in liver phenotypes in mouse models of Alagille syndrome.

1017 **Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis**

Z. M. Younossi, S. Zelber-Sagi, J. V. Lazarus, V. W.-S. Wong, Y. Yilmaz, A. Duseja, Y. Eguchi, L. Castera, M. G. Pessoa, C. P. Oliveira, M. El-Kassas, E. Tsochatzis, J.-G. Fan, C. W. Spearman, F. Tacke, M. I. Castellanos Fernandez, N. Alkhouri, J. M. Schattenberg, M. Romero-Gómez, M. Noureddin, A. M. Allen, J. P. Ong, S. K. Roberts, J. H. Shubrook, P. Burra, R. Kohli, A. Kautz, A. G. Holleboom, B. Lam, S. Isaacs, P. Macedo, A. Gastaldelli, L. Henry, D. Ivancovsky-Wajcman, F. Nader, L. de Avila, J. K. Price, H. E. Mark, M. Villota-Rivas, A. Barberá, M. Kalligeros, L. H. Gerber, and S. A. Alqahtani

Using the most recent global guidance/guideline documents on the care of individuals with metabolic dysfunction-associated steatotic liver disease and a Delphi process, consensus recommendations were generated to provide an easy-to-use assistance to busy clinicians for providing cutting-edge optimal care to these patients.

RESEARCH LETTERS

- 1033** **Out-of-Pocket Costs for Colonoscopy Preparation Persist Despite Affordable Care Act Mandate: Insights From a Large Real-World Dataset**
E. D. Shah, A. H. Calderwood, K. McBride, P. Sharaf, and D. L. Halberg
- 1036** **Association of US Preventive Services Task Force Guideline Expansion With Colorectal Cancer Screening Uptake and Recommendations Among Adults Aged 45–49 Years**
Y.-R. Hong, R. Liu-Galvin, and Z. Xie
- 1039** **Spatial Transcriptomics of Hirschsprung Disease Resection Margins Marks Differential Gene Expression in Myenteric Plexus**
I. A. M. van Thiel, J. J. T. H. Roelofs, R. R. Gorter, L. W. E. Van Heurn, W. J. De Jonge, and J. P. M. Derikx

SPECIAL ARTICLES

- 1043** **Defining Organ Failures in Patients With Cirrhosis: Consensus Statements**
J. S. Bajaj, D. L. Shawcross, A. Choudhury, C. J. Karvellas, J. G. O'Leary, J. Trebicka, A. V. Kulkarni, S. Marciano, S. K. Asrani, M. Premkumar, D. Thabut, Q. Xie, M. Sonderup, S. I. Strasser, A. Q. Faria, M. R. Alvares-da-Silva, A. Torre, J. C. Lai, Q. Ning, N. Verma, S. Chirapongsathorn, M. Mendizabal, S. Treeprasertsuk, W. Bernal, L. B. VanWagner, R. Maiwall, S. Piano, A. Albillos, G. Garcia-Tsao, P. Angeli, K. R. Reddy, F. Wong, R. Moreau, S. K. Sarin, and P. S. Kamath

CLINICAL PRACTICE UPDATES

- 1063** **AGA Clinical Practice Update on Management of Hepatitis Delta: Commentary**
T. Kushner, S. M. Cohen, J. Ahn, and R. J. Wong

GASTRO DIGEST

- 1070** **Endoscopist Adenoma Detection Rates and Subsequent Risks of Colorectal Cancer**
N. Forbes
- 1070** **Can Inebilizumab Change the Management of IgG4-Related Disease?**
M. Arvanitakis
- 1071** **Serotonin's New Frontier: SSRIs Unveiled as Cancer Immunotherapy**
R. Singh and K. G. Margolis
- 1072** **Novel Insights Into the Progression of α 1-Antitrypsin Deficiency-Associated Liver Disease Using Artificial Intelligence-Driven Deep Visual Proteomics**
P. Manickavel and M. Bhat

CORRESPONDENCE

- 1074** **Optimizing the Multi-HCC Model: Implications for Clinical Decision-Making and Transplant Prioritization**
K. Wang
- 1075** **Comments on "Model of Urgency for Liver Transplantation in Hepatocellular Carcinoma: A Practical Model to Prioritize Patients With Hepatocellular Carcinoma on the Liver Transplant Waitlist"**
S. Jing and J. Song
- 1075** **Refining Multi-HCC for Balanced Urgency and Utility**
Q. Pan and Y. Zhou
- 1076** **Reply**
V. Charu, A. J. Kwong, and J. S. Norman

- 1077 Personalized Dosing Strategies: The Missing Link in Glepaglutide Therapy for Short Bowel Syndrome**
X. Hu, X. Gu, and J. Sun
- 1078 Glepaglutide in Short Bowel Syndrome: Promising, But Questions Remain**
G. Sharma
- 1079 Potential and Challenges of Glepaglutide for SBS-IF**
S. Yang and Y. Lu
- 1080 Reply**
P. B. Jeppesen
- 1080 Reflections on the Use of Preclinical Protein Signatures for Inflammatory Bowel Disease Diagnosis**
L. Yang, C. Yang, J. Tang, G. Liu, and L. Yuan
- 1081 Comments on "Preclinical Protein Signatures of Crohn's Disease and Ulcerative Colitis: A Nested Case-Control Study Within Large Population-Based Cohorts"**
P. Wang, J. Wang, P. Zhang, and W. Xiao
- 1082 Refining Predictive Models in Preclinical Inflammatory Bowel Disease: Need for Expanded Validation and Clinical Translation**
Z. Tian and Y. Huang
- 1083 Reply**
O. Grännö, D. Bergemalm, B. Salomon, and J. Halfvarson
- 1084 Exploring the Role of Wearable Devices in Inflammatory Bowel Disease Management**
D. Liu, Y. Wei, and J. Wan
- 1085 Inflammation Is a Large Dataset of Heartbeats, Groceries, Night Rest, and More**
P. Bossuyt, I. De Nollin, T. De Moor, G. Trekels, I. Maes, G. Dewulf, and L. Pouillon
- 1087 Reply**
R. P. Hirten and B. E. Sands
- 1088 Comments on "Postoperative Endoscopic Outcomes in the MESOCOLIC Trial Investigating Mesenteric-Based Surgery for Crohn's Disease"**
W. A. Bemelman, A. E. G. Haanappel, M. Duijvestein, E. M. L. van der Does de Willebois, and C. J. Buskens
- 1089 Response to MESOCOLIC Trial Interim Analysis**
S. R. Brown, J. Hall, L. Hancock, and E. Herbert
- 1090 Reply**
M. Duan, J. C. Coffey, and Y. Li
- 1091 Mechanistic Insights Into Prucalopride's Role in Irritable Bowel Syndrome Treatment: Schwann-like Enteric Glial Cells as Therapeutic Targets**
Y. Zhao and M. P. Peppelenbosch
- 1092 Reply**
J. D. Windster, K. Parikh, and M. M. Alves

- 1093 Describing Rates of Post-Colonoscopy Colorectal Cancer: Potential Risks as Well as Benefits?**
A. Gupta, A. Metz, and F. Macrae
- 1093 Reply**
N. S. van Roermund, J. E. G. Ijspeert, and E. Dekker
- 1095 Clarifying the Causal Role of HIF-2 α in Obesity-Associated Esophageal Barrier Dysfunction: Mechanism or Marker?**
Z. Tian, Y. Huang, Z. Yang, S. Yin, F. Zhang, and H. Yang
- 1096 Corrigendum**

Access to the full content of Gastroenterology Online is available to all subscribers!

AGA members have seamless access to full *Gastroenterology* content from the AGA Web site. Simply sign in to <http://www.gastro.org>, visit the Publications section of the Web site, and click on *Gastroenterology*. You will be directed to the Journal Web site and will have full access to all content without having to supply a different username and password. Members can also visit <http://www.gastrojournal.org> directly and click on "Activate Online Access." Nonmember subscribers must create an online user account and activate their subscription to access the full text of articles on *Gastroenterology* Online. To activate your individual online subscription, please visit <http://www.gastrojournal.org> and click on "Activate Online Access." To activate your account, you

will need your subscriber account or member number, which you can find on your mailing label, (AGA members must use their 10-digit member number, including leading zeros). If you have any questions regarding your online subscription please call Elsevier Customer Service at (800) 654-2452.

Institutional access to *Gastroenterology* Online will be allowed only by limited site licensing. Further instructions will be available online. Personal subscriptions to *Gastroenterology* Online are for individual use only and may not be transferred. Use of *Gastroenterology* Online is subject to agreement to the terms and conditions of use as indicated online.

AGA Member Number

Sample
mailing
label

GAST0000101864
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001

Your Account Number

1GAST V91-4 1234567-8
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001